| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
4 companies
Myers Scott Dunseth is a Director at Zentalis Pharmaceuticals, Inc. with holdings across 4 companies. Recent SEC Form 4 filings include 4 buys and 0 sells.
Estimated insider holdings value: $6.8M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 22, 2025 | DVAX Dynavax Technologies Corp | Director | Buy | 3,800 | $10.82 | $41,116.00 | +12.2% | +2.9% | - | |
| Apr 30, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | Director | Buy | 21,000 | $1.40 | $29,372.70 | +8.1% | -4.9% | +182.4% | |
| Apr 12, 2023 | VRDN Viridian Therapeutics, Inc.\de | Chief Executive Officer | Buy | 4,000 | $25.37 | $101,478.80 | +1.6% | -18.1% | -35.3% | |
| Mar 13, 2023 | VRDN Viridian Therapeutics, Inc.\de | Chief Executive Officer | Buy | 5,500 | $29.15 | $160,324.45 | +2.2% | -11.6% | -39.0% |